Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6P93J)

Drug Name
API-023 Drug Info
Synonyms AGN-201904; Proton pump inhibitor prodrug, Alevium; Proton pump inhibitor prodrug, Allergan; AGN-201904-Z; Omeprazole prodrug (GERD), Alevium
Indication
Disease Entry ICD 11 Status REF
Gastroesophageal reflux disease DA22.Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM6P93J

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Gastric H(+)/K(+) ATPase alpha (ATP4A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dexlansoprazole DM1DBV5 Erosive esophagitis DA25.0 Approved [3]
Rabeprazole DMMZXIW Bacterial infection 1A00-1C4Z Approved [4]
AG-SPT201 DMJRQDG Ulcerative colitis DD71 Phase 3 [5]
Saliphenylhalamide DMLMRGH Solid tumour/cancer 2A00-2F9Z Preclinical [2]
PA-10040 DMELTM2 Cardiovascular disease BA00-BE2Z Investigative [2]
CA-50040 DMCLN6M Colorectal cancer 2B91.Z Investigative [2]
ARH-1029 DM8NETP Helicobacter infection DA42-DA63 Investigative [2]
OPC-22575 DMO4WH9 Ulcerative colitis DD71 Investigative [2]
CDRI-85/92 DMQDA5W Stomach ulcer DA60.Z Investigative [2]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gastric H(+)/K(+) ATPase alpha (ATP4A) TTF1QVM ATP4A_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT00325715) AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers. U.S. National Institutes of Health.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 849).
3 Clinical pipeline report, company report or official report of Takeda (2009).
4 Review article: rabeprazole's tolerability profile in clinical trials. Aliment Pharmacol Ther. 1999 Oct;13 Suppl 5:17-23.
5 Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. J Gastroenterol Hepatol. 1999 Mar;14(3):251-7.